Enanta Pharmaceuticals | ENTA - Net Income


Enanta Pharmaceuticals reported $-22.29M in Net Income for its fiscal quarter ending in December of 2024.





Net Income Change Date
AbbVie USD 3.61B 2.92B Jun/2026
Amgen USD 2.38B 556M Jun/2026
Anika Therapeutics USD 292K 2.62M Dec/2025
Arrowhead Research USD -194.28M 61.55M Jun/2026
AstraZeneca USD 2.51B 573M Jun/2026
BioCryst Pharmaceuticals USD 78.4M 167.45M Jun/2026
Biogen USD 97.5M 222M Jun/2026
Bristol-Myers Squibb USD 3.32B 640M Jun/2026
Enanta Pharmaceuticals USD -22.29M 93.76M Dec/2024
Gilead Sciences USD -10.5B 12.52B Jun/2026
GlaxoSmithKline GBP 435M 1.3B Jun/2026
Halozyme Therapeutics USD 229.91M 79.86M Jun/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Immunic USD -19.3M 6.28M Dec/2025
Incyte USD 585.6M 282.27M Jun/2026
Insmed USD -13.24M 150.32M Jun/2026
Ionis Pharmaceuticals USD -114.65M 21.65M Jun/2026
J&J USD 210M 5.32B Sep/2026
Karyopharm Therapeutics USD -22.39M 79.81M Mar/2026
Ligand Pharmaceuticals USD 48.51M 61.85M Jun/2026
Merck USD -1.34B 2.9B Jun/2026
Neurocrine Biosciences USD 144.4M 53.5M Jun/2026
Novartis USD 3.26B 108M Jun/2026
Novavax USD 17.53M 219.91M Dec/2025
Pfizer USD -248M 2.94B Jun/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Vertex Pharmaceuticals USD 1.1B 68.4M Jun/2026